VFA
AMRI

Virtus Fund Advisers’s Albany Molecular Research Inc AMRI Stock Holding History

Virtus Fund Advisers’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,009
Closed -$40K – 2422
2014
Q2 		$40K Buy
+2,009
New +$34K ﹤0.01% 2023

Other funds holding AMRI

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Virtus Fund Advisers's AMRI Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Albany Molecular Research Inc (AMRI) in Q3 2014, closing a stake of 2,009 shares — an estimated $40K sold.

Virtus Fund Advisers first reported a position in AMRI in Q2 2014 and held it in 1 quarter. The position peaked at $40K in Q2 2014. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Albany Molecular Research Inc position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 2,009 Albany Molecular Research Inc shares in Q3 2014, an estimated $40K.
  • Virtus Fund Advisers first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Albany Molecular Research Inc position peaked at $40K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.